Inhibition of Telomerase Activity by Preventing Proper Assemblage

Biochemistry

Volumn 43, Issue 2, 2004, Pages 334-343

  Keppler, Brian R ^a   Jarstfer, Michael B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSOCIATION REACTIONS; CHROMOSOMES; DRUG PRODUCTS; RNA; TUMORS;

CATALYTIC SUBUNITS;

ENZYME INHIBITION;

ANTINEOPLASTIC AGENT; OLIGONUCLEOTIDE; RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER CELL; CATALYSIS; CHROMOSOME; COMPLEX FORMATION; CONTROLLED STUDY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBUNIT; ENZYME SYNTHESIS; HUMAN; HYBRIDIZATION; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING;

CONSERVED SEQUENCE; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE INHIBITORS; RNA; RNA, COMPLEMENTARY; TELOMERASE;

EID: 0347724051     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi035583e     Document Type: Article

References (45)

1. Rhodes, D., Fairall, L., Simonsson, T., Court, R., and Chapman, L. (2002) Telomere architecture. EMBO Rep. 3, 1139-45.
2. Cong, Y. S., Wright, W. E., and Shay, J. W. (2002) Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 66, 407-25.
3. Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., Bacchetti, S., Haber, D. A., and Weinberg, R. A. (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-95.
4. Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., and Cech, T. R. (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-9.
5. Feng, J., Funk, W. D., Wang, S. S., Weinrich, S. L., Avilion, A. A., Chiu, C. P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) The RNA component of human telomerase. Science 269, 1236-41.
6. Masutomi, K., and Hahn, W. C. (2003) Telomerase and tumorigenesis. Cancer Lett. 194, 163-72.
7. White, L. K., Wright, W. E., and Shay, J. W. (2001) Telomerase inhibitors. Trends Biotechnol. 19, 114-20.
8. Saretzki, G. (2003) Telomerase inhibition as cancer therapy. Cancer Lett. 194, 209-19.
9. Strahl, C., and Blackburn, E. H. (1996) Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16, 53-65.
10. Melana, S. M., Holland, J. F., and Pogo, B. G. (1998) Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. 4, 693-6.
11. Murakami, J., Nagai, N., Shigemasa, K., and Ohama, K. (1999) Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur. J. Cancer 35, 1027-34.
12. Gomez, D. E., Tejera, A. M., and Olivero, O. A. (1998) Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment. Biochem. Biophys. Res. Commun. 246, 107-10.
13. Neidle, S., and Read, M. A. (2000) G-quadruplexes as therapeutic targets. Biopolymers 56, 195-208.
14. Lyu, S. Y., Choi, S. H., and Park, W. B. (2002) Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch. Pharm. Res. 25, 93-101.
15. Naasani, I., Seimiya, H., and Tsuruo, T. (1998) Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. 249, 391-6.
16. Kim, M. Y., Vankayalapati, H., Shin-Ya, K., Wierzba, K., and Hurley, L. H. (2002) Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J. Am. Chem. Soc. 124, 2098-9.
17. Naasani, I., Seimiya, H., Yamori, T., and Tsuruo, T. (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59, 4004-11.
18. Hayakawa, N., Nozawa, K., Ogawa, A., Kato, N., Yoshida, K., Akamatsu, K., Tsuchiya, M., Nagasaka, A., and Yoshida, S. (1999) Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 38, 11501-7.
19. Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., Lauritsch, I., Muller, E., Pascolo, E., Sauter, G., Pantic, M., Martens, U. M., Wenz, C., Lingner, J., Kraut, N., Rettig, W. J., and Schnapp, A. (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20, 6958-68.
20. Elayadi, A. N., Demieville, A., Wancewicz, E. V., Monia, B. P., and Corey, D. R. (2001) Inhibition of telomerase by 2′-0-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. 29, 1683-9.
21. Hamilton, S. E., Simmons, C. G., Kathiriya, I. S., and Corey, D. R. (1999) Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6, 343-51.
22. Chen, J. L., Blasco, M. A., and Greider, C. W. (2000) Secondary structure of vertebrate telomerase RNA. Cell 100, 503-14.
23. Chen, J. L., Opperman, K. K., and Greider, C. W. (2002) A critical stem-loop structure in the CR4-CR5 domain of mammalian telomerase RNA. Nucleic Acids Res. 30, 592-7.
24. Singer, M. S., and Gottschling, D. E. (1994) TLC1: template RNA component of Saccharomyces cerevisiae telomerase. Science 266, 404-9.
25. Blasco, M. A., Funk, W., Villeponteau, B., and Greider, C. W. (1995) Functional characterization and developmental regulation of mouse telomerase RNA. Science 269, 1267-70.
26. Tsao, D. A., Wu, C. W., and Lin, Y. S. (1998) Molecular cloning of bovine telomerase RNA. Gene 221, 51-8.
27. Romero, D. P., and Blackburn, E. H. (1991) A conserved secondary structure for telomerase RNA. Cell 67, 343-53.
28. Lingner, J., Hendrick, L. L., and Cech, T. R. (1994) Telomerase RNAs of different ciliates have a common secondary structure and a permuted template. Genes Dev. 8, 1984-98.
29. Martin-Rivera, L., and Blasco, M. A. (2001) Identification of functional domains and dominant negative mutations in vertebrate telomerase RNA using an in vivo reconstitution system. J. Biol. Chem. 276, 5856-65.
30. Mitchell, J. R., and Collins, K. (2000) Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase. Mol. Cell. 6, 361-71.
31. Tesmer, V. M., Ford, L. P., Holt, S. E., Frank, B. C., Yi, X., Aisner, D. L., Ouellette, M., Shay, J. W., and Wright, W. E. (1999) Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro. Mol. Cell. Biol. 19, 6207-16.
32. Bachand, F., and Autexier, C. (2001) Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions. Mol. Cell. Biol. 21, 1888-97.
33. Beattie, T. L., Zhou, W., Robinson, M. O., and Harrington, L. (2000) Polymerization defects within human telomerase are distinct from telomerase RNA and TEP1 binding. Mol. Biol. Cell 11, 3329-40.
34. Chen, J. L., and Greider, C. W. (2003) Determinants in mammalian telomerase RNA that mediate enzyme processivity and cross-species incompatibility. EMBO J. 22, 304-14.
35. Ly, H., Xu, L., Rivera, M. A., Parslow, T. G., and Blackburn, E. H. (2003) A role for a novel "trans-pseudoknot" RNA-RNA interaction in the functional dimerization of human telomerase. Genes Dev. 17, 1078-83.
36. Colgin, L. M., Wilkinson, C., Englezou, A., Kilian, A., Robinson, M. O., and Reddel, R. R. (2000) The hTERTα splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2, 426-432.
37. Maxam, A. M., and Gilbert, W. (1977) A new method for sequencing DNA. Proc. Natl. Acad. Sci. U.S.A. 74, 560-4.
38. Ly, H., Blackburn, E. H., and Parslow, T. G. (2003) Comprehensive structure-function analysis of the core domain of human telomerase RNA. Mol. Cell. Biol. 23, 6849-56.
39. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M. (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-22.
40. Eckstein, F. (2000) Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 10, 117-21.
41. Corey, D. R. (2002) Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 21, 631-7.
42. Pruzan, R., Pongracz, K., Gietzen, K., Wallweber, G., and Gryaznov, S. (2002) Allosteric inhibitors of telomerase: oligonucleotide N3′→ P5′ phosphoramidates. Nucleic Acids Res. 30, 559-68.
43. Antal, M., Boros, E., Solymosy, F., and Kiss, T. (2002) Analysis of the structure of human telomerase RNA in vivo. Nucleic Acids Res. 30, 912-20.
44. Ren, X., Gavory, G., Li, H., Ying, L., Klenerman, D., and Balasubramanian, S. (2003) Identification of a new RNA·RNA interaction site for human telomerase RNA (hTR): structural implications for hTR accumulation and a dyskeratosis congenita point mutation. Nucleic Acids Res. 31, 6509-15.
45. Yi, X., Tesmer, V. M., Savre-Train, I., Shay, J. W., and Wright, W. E. (1999) Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol. Cell. Biol. 19, 3989-97.